London based Alceus Bio is working on an in vivo CAR-T platform for solid tumors and recently was a recipient of a golden ticket award from AbbVie
Co-Founders Alex Evans and Alberto Conti talk about winning the golden ticket and how it has already been helping them, and share advice for others who might be interested in applying one day. Plus, general advice for new bio entrepreneurs.
6 hours ago
London based Anomer Bio has a small molecule platform that aims to change how cells make and process glycans
Inspired by the Nobel Prize winning work of Carolyn Bertozzi, Co-Founder and CEO Sophie James describes the science that underlies the company. Plus, moving into Victoria House in London and her advice for other entrepreneurs.
7 hours ago
From Cambridge, UK: PlaqueTec has a unique liquid biopsy system and multi omic analysis approach that aims to profile the underlying biology of atherosclerosis
General Manager Simon Williams describes how the liquid biopsy works and what PlaqueTec is doing in its analysis of the samples. The company is current in an approximately 300 person clinical trial that will finish up towards the end of next year.
2 days ago
Lund based Asgard Therapeutics aims to turn tumor cells into a type of dendritic cell inside the body so that the immune system can learn the tumor's signature and fight it systemically
Co-Founder and CEO Cristiana Pires describes this unique approach, which is in late stage pre-IND work and recently was presented at AACR and ASGCT. The company already has an impressive roster of investors backing it.
2 days ago
Lund based BioInvent has had a busy week with a presentation of one program in ovarian cancer at ASCO, and two more coming up in hematological cancers at the upcoming EHA Congress
Chief Scientific Officer Björn Frendéus walks us through the companies antibody discovery platform, and the two lead clinical assets, which target TNFR2 and FcγRIIB.
2 days ago
Cambridge, UK based Cyclana Bio aims to find a cure for endometriosis through a deep understanding of human biology and the extracellular matrix
Co-Founder and CEO Léa Wenger, who has personally had this condition, describes the company's work and her strong belief that the company must better understand the human biology involved. In that regard, they have a unique program to collect and study menstral blood from donors. Cyclana was recently accepted into Eli Lilly's Virtual Gateway accelerator program.
3 days ago
GSK and London based Engitix Therapeutics announced today they will collaborate on first in class targets for liver fibrosis regression using Engitix's extracellular matrix (ECM) discovery platform
GSK will pay Engitix approximately $59M up front and up to approximately $157M more in potential milestones. Engitix Co-Founder and CEO Giuseppe Mazza discusses the deal and the company's platform.
3 days ago
From the New York Stock Exchange, AstraZeneca CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more
In New York to ring the open bell in celebration of the listing of the AstraZeneca's ordinary shares on the NYSE earlier this year, he discusses M&A, PD-1 x VEGF, PD-1 x TIGIT, Baxfendy, and the company's efforts in obesity ahead of this weekend's American Diabetes Association Scientific Sessions.
6 days ago
Protuoso Biosciences exited stealth this past week with the goal of developing multifunctional MUXBODY biologics, fusion proteins that integrate diverse modalities into a single therapy
Co-Founder & CEO Willie Xiang discusses the platform and the company's progress to getting them into the clinic. Current programs target cardiometabolic diseases and solid tumors.
7 days ago
HEPHAISTOS Pharma is developing a TLR4 agonist meant to overcome immunosuppressive tumor environments. It has benefited from Paris Saclay Cancer Cluster's BOOST activator program
CEO Frédéric Caroff describes the program, and how it is meant to activate both the innate and adaptive immune systems, and how the support of BOOST has helped the company.
Jun 4
Anne Vanet co-founded Lafame, an all female founded company that uses software to analyze viral and oncology mutations to improve the design of trials and drug development
She describes the idea behind the company, her take on the French biotech ecosystem, and her advice for future biotech entrepreneurs.
Jun 4
Ipsen acquired ImCheck Therapeutics, a Marseille based company with a unique immune-oncology antibody, for $350M last year. ImCheck's former CEO, Pierre d'Epenoux tells the story behind it
He discusses the idea behind the company and the buyout, and how ImCheck was a product of the broader French biotech ecosystem.
Jun 4
Orakl Oncology has an AIxBio platform that is unique because it captures signals from six dimensions of life. They believe it gives their model high predictive accuracy
Co-Founder & CEO Fanny Jaulin describes the platform, which integrates data from DNA, RNA, proteins, cells, tissues, and real world patient data. They are starting with pancreatic and colorectal cancer and believe their database for these cancers is the largest of its kind.
Jun 3
Ascidian and Lilly signed a collaboration today to use Ascidian's RNA exon editing platform for monogenic kidney diseases, potentially worth up to $1.9 billion in milestones
Ascidian CEO Mike Ehlers tells us about the deal and discusses the technology and the potential benefits of it over DNA editing and other genetic medicine approaches.
Jun 3
ASCO 2026: Celcuity CEO Brian Sullivan discusses the late breaking data for the PAM inhibitor gedatolisib that was just presented at ASCO - doubled the likelihood of survival in HR+/HER2- breast
These data were for patients with the PIK3CA mutation. The median PFS for the gedatolisib triplet combo was 11.1 months versus 5.6 months, compared to alpelisib plus fulvestrant.
Jun 2
ASCO 2026: "If you look at what happened to KRAS at this conference....we are on that path with beta-catenin." Iterion CEO Rahul Aras describes his company's approach to WNT/beta-catenin and ASCO data
He describes the biology of WNT/beta-catenin, an undruggable target for decades and why he believes there is now room for optimism. Iterion presented an update of its TBL1 inhibitor in hepatocellular carcinoma today in an oral presentation at ASCO.
Jun 1
ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this
He describes the data, which showed a 17.3 months median OS in 55 patients vs. 8.5 months for SoC, and descrbies why he believes the therapy has an ideal profile for first line patients. A phase three study is already active and accruing patients.
Jun 1
ASCO 2026: Summit Therapeutics' Co-CEO and Chief Strategy Officer discuss the HARMONi-6 ASCO data release for the PD-1xVEGF bi-specific antibody Ivonescimab
Maky Zanganeh and Dave Gancarz share their take on the result, which at the topline showed that Ivonescimab plus chemo reduced the risk of death by 34% vs the PD-1 Tislelizumab plus chemo, and they are given the opportunity to respond to some of the pushback heard around McCormick Place.
Jun 1
ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology
Ken Keller and John Tsai describe which other modalities besides ADCs that Daiichi thinks about, and cover ASCO and pipeline progress on Enhertu (Her2), Datroway (Trop2), the company's B7-H3.
Jun 1
ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart
CEO Aron Knickerbocker walks us through the data, which included a doublet regimen with aldesleukin and a triplet that also included nivolumab, and suggests that Aulos is planning to meet with FDA about a potential accelerated approval pathway for the therapy.
May 31
ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities
He highlights the importance of the long term Brukinsa data, which is the top selling BTK inhibitor today. Plus, we discuss degraders, antibody-drug conjugates, and bispecifics.
May 31
ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs
Current CEO David Chang describes why now was the right time to pass the baton to Zach Roberts, and why they are both excited about the company's 1L large B-cell lymphoma program, and learnings on why they believe using a combo approach of CD19 and CD70 is an effective way to go about allogeneic therapy in the future.
May 31
ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck
CEO Claire Mazumdar describes the ASCO data, and updates us on the phase 2/3 study, which is already in the phase 3 portion. Bicara hopes to use the study to eventually gain an accelerated approval.
May 31
ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
May 31
ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications
Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.
May 31
ASCO 2026: Olema Oncology's CEO Sean Bohen highlights new KAT6 data in breast and prostate cancer, and updates us on the progress of palazestrant's pivotal trials
He discusses the potential utility of KAT6 after presenting monotherapy data, and how it could be used in combination with palazestrant (a complete estrogen receptor antagonist). Plus, learning from the field in the estrogen receptor space, and an update on the progress of Olema's own pivotal tirals. The company's OPERA-1 monotherapy phase 3 of palazestrant is schedule to read in the fall.
May 30
ASCO 2026: Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMA
She describes Vir's PRO-XTEN masking technology and why she believes it has advantages vs others in development. Plus, a summary of the company's PSMA data, and how she believes the masking technology has played such a critical role.
May 30
ASCO 2026: Immatics is presenting data on its second generation PRAME targeting cell therapy in gynecological cancers and synovial sarcoma
CEO Harpreet Singh walks us though the data and reminds us how this second generation approach uses CD4+ helper T-cells in addition to CD8 for additional firepower.
May 30
.png){kind=logo}
